Mattel Could Break Apart, Doesn't Need to Pursue an Outright Sale -- Market Talk
Dow Jones2026/10/07 17:301330 ET - Ariel Investments doesn't necessarily want Mattel to sell itself. The asset-management firm, which has a 5.4% stake in the toymaker, says Barbie-doll maker should retain an independent financial advisory firm to explore various strategic alternatives, including a divestiture of significant assets, a merger or an outright sale. "We think (the board) will do the right thing for shareholders," Ariel Co-CEO John Rogers says in an interview with CNBC. "The leaders there have shown a history of doing the right thing." (connor.hart@wsj.com) (END) Dow Jones Newswires October 07, 2026 13:30 ET (17:30 GMT)
1330 ET - Ariel Investments doesn't necessarily want Mattel to sell itself. The asset-management firm, which has a 5.4% stake in the toymaker, says Barbie-doll maker should retain an independent financial advisory firm to explore various strategic alternatives, including a divestiture of significant assets, a merger or an outright sale. "We think (the board) will do the right thing for shareholders," Ariel Co-CEO John Rogers says in an interview with CNBC. "The leaders there have shown a history of doing the right thing." (connor.hart@wsj.com)
(END) Dow Jones Newswires
October 07, 2026 13:30 ET (17:30 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
